Will Authorized Generic Nucynta Launch and New Credit Facility Change Collegium Pharmaceutical's (COLL) Narrative? [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
and highlighting new authorized generic supply agreements for Nucynta and Nucynta ER with Hikma Pharmaceuticals USA Inc. Collegium also closed a US$980 million syndicated credit facility in late 2025, replacing a prior term loan and providing additional undrawn capacity to support debt repayment and future business development. Now we'll examine how the authorized generic Nucynta launch with Hikma could reshape Collegium's existing investment narrative and risk profile. We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year . See the full list for free. To own Collegium, you have to be comfortable with a concentrated pain and ADHD portfolio and the regulatory and generic risks that come with it, while believing Jornay PM and abuse deterrent technologies can support earnings. The 2026 revenue guidance and Hikma authorized generics do not fundamentally change the biggest near term swing factors, but they could influence how investors view exposur
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual ConferenceGlobeNewswire
- Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 [Yahoo! Finance]Yahoo! Finance
- Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? [Yahoo! Finance]Yahoo! Finance
- Is It Time To Reassess Collegium Pharmaceutical (COLL) After Its Strong Five Year Share Price Run? [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical (NASDAQ:COLL) had its price target lowered by analysts at Barclays PLC from $58.00 to $56.00. They now have an "overweight" rating on the stock.MarketBeat
COLL
Earnings
- 11/6/25 - Beat
COLL
Sec Filings
- 1/8/26 - Form 8-K
- 12/30/25 - Form 8-K
- 12/17/25 - Form 144
- COLL's page on the SEC website